Colchicine Trial Shows No Significant Benefits

A large multinational trial, CLEAR SYNERGY (OASIS 9), involving over 7000 patients, found no significant benefit of colchicine in preventing major cardiovascular events after an acute myocardial infarction. The study showed that event rates for cardiovascular death, MI, stroke, and revascularization were similar between colchicine and placebo groups over five years. The findings challenge current guidelines recommending colchicine for post-MI treatment, suggesting its role is uncertain, with the only notable side effect being increased diarrhea risk.